

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **COMMON SPLENDOR INTERNATIONAL HEALTH INDUSTRY GROUP LIMITED**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 286)**

### **FRAMEWORK AGREEMENT WITH SHENG HUI TANG IN RELATION TO THE FORMATION OF ASSISTIVE REPRODUCTION INDUSTRY FUND**

This announcement is made by Common Splendor International Health Industry Group Limited (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

### **COOPERATION FRAMEWORK AGREEMENT WITH S.H.T. HEALTHCARE GROUP**

The board of directors (the “**Board**”) of the Company is pleased to announce that, on 5 May 2017 (after trading hours), the Company entered into a non-legally binding cooperation framework agreement (the “**Framework Agreement**”) with 深圳市前海聖輝堂醫療健康產業投資集團有限公司 (Shenzhen Qianhai Sheng Hui Tang Healthcare Industry Investment Group Co., Ltd.\*) (“**S.H.T. Healthcare Group**”), to cooperate closely in the region of healthcare by integrating both parties’ respective resources, on the basis of mutual benefit and reciprocity.

### **FRAMEWORK AGREEMENT**

The principal terms of the Framework Agreement are set out as follows:

Date: 5 May 2017 (after trading hours)

Parties: (i) The Company; and  
(ii) S.H.T. Healthcare Group  
(the “**Parties**”)

Formation of Proposed Fund: The Parties shall, through their respective fund management subsidiaries, establish a fund in the form of a limited partnership for future mergers and acquisitions in the healthcare industry (“**Proposed Fund**”).

The general partners of the Proposed Fund shall be the respective subsidiaries of the Parties, and the Parties shall seek individuals or institutions to participate as limited partner of the Proposed Fund. The target size of the Proposed Fund is RMB1 billion.

The Proposed Fund is expected to invest in the region of assistive reproduction, infertility and precision healthcare.

Responsibilities of the Proposed Fund and the Company’s right to first offer: S.H.T. Healthcare Group shall take the lead in the design, material production, communication, roadshow and product preparation work. The Company shall provide support in terms of formation of the Proposed Fund and capital funding.

The Parties shall jointly manage and make decisions on execution and investments of the Proposed Fund, including matters relating to feasibility of healthcare project development, research on projects, investment targets and risk management. The funds of the Proposed Fund shall be jointly managed by the Parties. The Company has right of first offer to take up projects of the Proposed Fund in the event that the Proposed Fund decides on an exit.

## **INFORMATION ON S.H.T. HEALTHCARE GROUP**

So far as the Directors understand from S.H.T. Healthcare Group, it is an investment group focused on development of high-end healthcare industry. S.H.T. Healthcare Group has experience in healthcare investment, operation and healthcare institutions reform. Further, it has establishments relating to assistive reproduction, stem cells, cancer diagnosis, high-end life preservation and elderly care industries in various locations in the PRC, including Shenzhen, Shanghai, Guangzhou, Dongguan, Nanchang and Shangrao, and S.H.T. Healthcare Group has entered into strategic cooperation agreements with certain local governments and research centres to consolidate capital and resources for development in the PRC healthcare industry.

To the best of the Directors’ knowledge, information and belief, and having made all reasonable enquiries, S.H.T. Healthcare Group and its ultimate beneficial owners are independent of, and not connected with, the Company and any of its connected persons (as defined in the Listing Rules).

## **REASONS AND BENEFITS FOR ENTERING INTO THE FRAMEWORK AGREEMENT**

The Group is proactively looking for life healthcare investment and development opportunities. Assistive reproduction is one of the core elements in life healthcare arena.

The Company entered into the Framework Agreement with the intention of leveraging on the Parties' respective strength, resources and expertise to jointly develop in this arena. Using a joint investment fund to develop and expand business is beneficial to both parties without occupying their capital. This provides an exit mechanism to achieve investment returns while this also aids the Company to look for development opportunities.

**The Board wishes to emphasise that the implementation of the cooperation and transactions contemplated under the Framework Agreement (if any) are subject to the definitive agreement(s) to be entered into between the Parties, and such cooperation and transactions may not necessarily be implemented as contemplated or at all. Shareholders of the Company and potential investors should exercise caution when dealing in Company's securities.**

By order of the Board  
**Common Splendor International  
Health Industry Group Limited**  
**Cheung Wai Kuen**  
*Chairman*

Hong Kong, 5 May 2017

*As at the date of this announcement, the Board comprises Mr. Cheung Wai Kuen, Mr. Cheng Hau Yan and Mr. Ye Jiong Xian as executive Directors and Mr. Lin Jiang and Mr. Bai Yinghai as non-executive Directors and Mr. Mai Yang Guang, Mr. Yau Chi Ming and Mr. Lam Chi Wing as independent non-executive Directors.*

\* *For identification purposes only*